Innovent News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that preclinical data on multiple novel bispecific antibodies as well as antibody-drug-conjugates (ADCs) from its oncology pipeline are presented at the American Association for Cancer Research (AACR) Annual Meetin

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announced that the preclinical results of IBI363 were published in Nature Cancer (IF=22.7). The publication entitled, "IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells".

Switching from buying IT assets to leasing them could cut up to 30% off the cost of IT equipment, says Zakhe Khuzwayo, co-founder and CFO of InnoVent.

China’s National Medical Products Administration has granted a breakthrough therapy designation to the KRAS G12C inhibitor IBI351 as monotherapy for previously treated patients with advanced colorectal carcinoma harboring a KRAS G12C mutation.

ITWeb’s smart computing industry portal looks at topics and trends on a host of issues across the enterprise. Wireless networks, new developments on the microchip front, the latest in computer viruses, monitors, printers and peripherals, and server sales and performance levels are some of the diverse topics that are covered in this section.